Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in an outbreak of SARS-CoV-2
Article Sidebar
Main Article Content
Downloads
Article Details
Copyright (c) 2020 Acik DY.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Thomson G (2020) COVID‐19: social distancing, ACE 2 receptors, protease inhibitors and beyond? Int J Clin Pract e13503. Link: https://bit.ly/3hkxLsA
Zhou F, Yu T, Du R, Fan G, Liu Y, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062. Link: https://bit.ly/3fh7biy
Yang X, Yu Y, Xu J, Shu H, Xia J (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8: 475-481. Link: https://bit.ly/3dZlnMU
Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708-1720. Link: https://bit.ly/2UyxRmQ
Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, et al. (2020) Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. Link: https://bit.ly/2Ap1r7r
Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, et al. (2020) Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi 48: E004. Link: https://bit.ly/2UycUs1
Korean Society of Infectious Diseases and Korea Centers for Disease Control and Prevention (2020) Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea From January 19 to March 10, 2020. J Korean Med Sci 35: e132. Link: https://bit.ly/37jDaf7
Li XC, Zhang J, Zhuo JL (2017) The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res 125: 21-38. Link: https://bit.ly/3dW2BFS
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan BK, et al. (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610. Link: https://bit.ly/3fikezV
Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, et al. (2016) Pre-fusion structure of a human coronavirus spike protein. Nature 531: 118–121. Link: https://go.nature.com/2ML8FW1
Xu X, Chen P, Wang J, Feng J, Zhou H, et al. (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63: 457-460. Link: https://bit.ly/2Ynrtjr
Wan Y, Shang J, Graham R, Baric RS, Li F (2020) Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 94: e00127. Link: https://bit.ly/2znKp9j
Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 1-4. Link: https://bit.ly/2XSV5Gi
Diaz JH (2020) Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 27. Link: https://bit.ly/2UytzMq
Xie X, Chen J, Wang X, Zhang F, Liu Y (2006) Age- and gender-related difference of ACE2 expression in rat lung. Life Sci 78: 2166-2171. Link: https://bit.ly/3cU9w0W
Ingelfinger JR (2009) Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 18: 79–84. Link: https://bit.ly/3hdUuXz
Sun ML, Yang JM, Sun YP, Su GH (2020) Inhibitors of RAS might Be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jiehe He Huxi Zazhi 43: 219-222. Link: https://bit.ly/3hise60
Phadke M, Saunik S (2020) Use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections – Novel mode of treatment. BMJ 368: m406. Link: https://bit.ly/2YtglkW
Kruse RL (2020) Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 9: 72. Link: https://bit.ly/2YnGZMi
Kuster GM, Pfister O, Burkard T, Zhou Q Twerenbold R, et al. (2020) SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur Heart J 41: 1801-1803. Link: https://bit.ly/2MQdtsY
Bernstein KE, Khan Z, Giani JF, Zhao T, Eriguchi M, et al. (2016) Overexpression of angiotensin-converting enzyme in myelomonocytic cells enhances the immune response. F1000Research 2016, 5(F1000 Faculty Rev): 393. Link: https://bit.ly/30vHcj2
Alfonso C, Han JO, Williams GS, Karlsson L (2001) The impact of H2-DM on humoral immune responses. J Immunol 167: 6348–6355. Link: https://bit.ly/30ud0F2
Abbas KA, Andrew HL, Pillai S (2007) Cellular and Molecular Immunology: 6th edition. Philadelphia, Saunders Elsevier 97-111. Link: https://bit.ly/3cYUwiI
Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, et al. (2013) A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 65: 1–46. Link: https://bit.ly/2MRM35W
Danilov SM, Sadovnikova E, Scharenborg N, Balyasnikova IV, Svinareva DA, et al. (2003) Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 31: 1301– 1309. Link: https://bit.ly/2AYIXe1
Esther CR, Howard TE, Marino EM, Goddard JM, Capecchi MR, et al. (1996) Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74: 953-965. Link: https://bit.ly/2MQJTnn
Harmer D, Gilbert M, Borman R, Clark KL (2002) Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532: 107-110. Link: https://bit.ly/30w1DMN
Kool M, Soullie T, Van Nimwegen M, Willart MAM, Muskens F, et al. (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205: 869-882. Link: https://bit.ly/2AnQByo
Neefjes J, Jongsma ML, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11: 823-836. Link: https://go.nature.com/3cR27Q7
Roche PA, Furuta K (2015) The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 15: 203-216. Link: https://bit.ly/2BWGCke
Zhao T, Bernstein KE, Fang J, Shen XZ (2017) Angiotensin converting enzyme affects the presentation of MHC class II antigen. Lab Invest 97: 764-771. Link: https://bit.ly/2MQnXZE
Saijonmaa O, Nyman T, Fyhrquist F (2007) Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages. Am J Physiol Heart Circ Physiol 292: H1917-1921. Link: https://bit.ly/37jHk6J
Shen XZ, Lukacher AE, Billet S, Williams IR, Bernstein KE (2008) Expression of angiotensin-converting enzyme changes major histocompatibility complex class I peptide presentation by modifying C termini of peptide precursors. J Biol Chem 283: 9957–9965. Link: https://bit.ly/2Yo8fu2
Khan Z, Shen XZ, Bernstein EA, Giani JF, Eriguchi M, et al. (2017) Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils. Blood 130: 328–339. Link: https://bit.ly/2XWfvyp
Pouwels KB, Visser ST, Hak E (2013) Effect of pravastatin and fosinopril on recurrent urinary tract infections. J Antimicrob Chemother 68: 708-714. Link: https://bit.ly/3fhIUZF
Liu ZY, Li TS, Wang Z, Xu ZJ, Wang HL, et al. (2003) Clinical features and therapy of 106 cases of severe acute respiratory syndrome. Chinese J Intern Med 42: 373-377. Link: https://bit.ly/2MO7EMP
Li TS, Qiu ZF, Han Y, et al. (2003) The alterations of T cell subsets of severe acute respiratory syndrome during acute phase. Chinese J Lab Med 5: 40-42.
Taisheng L, Zhifeng Q, Linqi Z, Han Y, He W, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis 189: 648–651. Link: https://bit.ly/2XRxYvJ
Ko JH, Park GE, Lee JY, Lee JY, Cho SY, et al. (2016) Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients. J Infect 73: 468-475. Link: https://bit.ly/3dZqnkE
Mohn KG, Cox RJ, Tunheim G, Berdal JE, Hauge AG, et al. (2015) Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLoS One 10: e0143281. Link: https://bit.ly/30rPgkW
Lin L, Lu LF, Cao W, Li T (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microb Infect 9. Link: https://bit.ly/2B2ME20
Bermejo-Martin JF, Lejarazu ROD, Pumarola T, Rello J, Almansa R, et al. (2009) Th1andTh17hypercytokinemiaasearlyhostresponse signature in severe pandemic influenza. Crit Care 13: R201. Link: https://bit.ly/2ApEIYU
Wang D, Hu B, Hu C (2020) Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061-1069. Link: https://bit.ly/2B0gmVo
Serrano-Villar S, Moreno S, Fuentes-Ferrer M, Sánchez-Marcos C, Avila M, et al. (2014) The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med 15: 40–49. Link: https://bit.ly/37neBO9
Kroger L, Vahasalo P, Tynjala P, et al. (2012) Medical treatment of juvenile idiopathic arthritis. Duodecim 128: 477-486.
Wikby A, Månsson IA, Johansson B, Strindhall J, Nilsson SE (2008) The immune-risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20–100 years of age. Biogerontology 9: 299–308. Link: https://bit.ly/2Uyt9Wl
Shao MJ, Zhu YJ, Qiu YE, Hu M, He YQ (2017) Changes in the Level of Immunoglobulins and CD4/CD8 Ratio in Young and Aged Mice with Estradiol Deficiency. Immunol Invest 46: 305–313. Link: https://bit.ly/2N13YYl
Bell EB, Sparshott SM, Drayson MT, Ford WL (1987) The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells. J Immunol 139: 1379–1384. Link: https://bit.ly/2Yt81BK
Rocha B, Dautigny N, Pereira P (1989) Peripheral T lymphocytes: Expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur J Immunol 19: 905-911. Link: https://bit.ly/2zo7Oax
Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, et al. (2006) Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 20: 1727-1736. Link: https://bit.ly/2MQtM9a
Riddler S, Aga E, Bosch R, Bastow B, Bedison M, et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiviral Therapy. J Infect Dis 213: 556-560. Link: https://bit.ly/2XWtdBn
Singh RP, Javaid M, Kataria R, Tyag M, Haleem A, et al. (2020) Significant Applications of Virtual Reality for COVID-19 Pandemic. Diabetes Metab Syndr 14: 661-664. Link: https://bit.ly/3dUwjLs